JP2004502640A5 - - Google Patents

Download PDF

Info

Publication number
JP2004502640A5
JP2004502640A5 JP2001557366A JP2001557366A JP2004502640A5 JP 2004502640 A5 JP2004502640 A5 JP 2004502640A5 JP 2001557366 A JP2001557366 A JP 2001557366A JP 2001557366 A JP2001557366 A JP 2001557366A JP 2004502640 A5 JP2004502640 A5 JP 2004502640A5
Authority
JP
Japan
Prior art keywords
adenosine
fibrosis
administering
subject
need
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001557366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004502640A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/004341 external-priority patent/WO2001058241A2/en
Publication of JP2004502640A publication Critical patent/JP2004502640A/ja
Publication of JP2004502640A5 publication Critical patent/JP2004502640A5/ja
Pending legal-status Critical Current

Links

JP2001557366A 2000-02-10 2001-02-12 肝繊維症、硬変症および脂肪肝を治療および予防するアデノシンａ２ａ受容体拮抗薬 Pending JP2004502640A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18154600P 2000-02-10 2000-02-10
PCT/US2001/004341 WO2001058241A2 (en) 2000-02-10 2001-02-12 Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver

Publications (2)

Publication Number Publication Date
JP2004502640A JP2004502640A (ja) 2004-01-29
JP2004502640A5 true JP2004502640A5 (enExample) 2005-02-03

Family

ID=22664744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001557366A Pending JP2004502640A (ja) 2000-02-10 2001-02-12 肝繊維症、硬変症および脂肪肝を治療および予防するアデノシンａ２ａ受容体拮抗薬

Country Status (11)

Country Link
US (1) US6555545B2 (enExample)
EP (1) EP1272897B1 (enExample)
JP (1) JP2004502640A (enExample)
AT (1) ATE394104T1 (enExample)
AU (2) AU3812401A (enExample)
CA (1) CA2398908C (enExample)
DE (1) DE60133887D1 (enExample)
DK (1) DK1272897T3 (enExample)
ES (1) ES2307593T3 (enExample)
PT (1) PT1272897E (enExample)
WO (1) WO2001058241A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6196459B1 (en) * 1998-05-11 2001-03-06 Ubiq Incorporated Smart card personalization in a multistation environment
WO2003080649A2 (en) * 2002-03-20 2003-10-02 Regents Of The University Of Minnesota Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors
ITRM20070088A1 (it) * 2007-02-19 2008-08-20 Francesco Fringuelli Composti derivati della colchicina, procedimento per la loro preparazione e usi in campo medico.
CN101842098A (zh) * 2007-08-10 2010-09-22 基因实验室技术有限公司 用于治疗病毒感染的含氮的二环化学实体
WO2009055021A1 (en) * 2007-10-26 2009-04-30 New York University School Of Medicine Methods and compositions for treating hepatic diseases
CA2711673A1 (en) * 2008-01-31 2009-08-06 Astellas Pharma Inc. Pharmaceutical compositions for treating fatty liver disease
US8536306B2 (en) 2008-10-01 2013-09-17 The Scripps Research Institute Human A2A adenosine receptor crystals and uses thereof
US20100204265A1 (en) * 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
BRPI1009398A2 (pt) 2009-03-13 2016-03-08 Advinus Therapeutics Private Ltd compostos de pirimidina fundida substituída
SI2408775T1 (sl) * 2009-03-20 2015-08-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Oksidirani derivati triazolilpurinov, ki so uprabni kot ligandi receptorja adenozina A2A, in njihova uporaba kot zdravila
EP2499142B1 (en) 2009-11-09 2016-09-21 Advinus Therapeutics Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
ES2579949T3 (es) 2010-02-05 2016-08-17 Heptares Therapeutics Limited Derivados de 1,2,4-triazin-4-amina
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
AU2018294557A1 (en) 2017-06-30 2020-01-02 Ryvu Therapeutics S.A. Imidazo(1,2-a)pyrazine modulators of the adenosine A2A receptor
AU2018389313B2 (en) 2017-12-19 2021-08-19 Impetis Biosciences Ltd. Pharmaceutical composition for the treatment of cancer
AU2019205661B2 (en) 2018-01-04 2022-06-30 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof
WO2020128036A1 (en) 2018-12-21 2020-06-25 Ryvu Therapeutics S.A. Modulators of the adenosine a2a receptor
AU2023454063A1 (en) 2023-07-17 2026-01-15 BioNTech SE Modulators of the adenosine a2a and a2b receptor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705658A (en) 1986-04-07 1987-11-10 Capsule Technology International, Ltd. Method for drying gelatin in the manufacture of hard shell gelatin capsules
US5063233A (en) 1986-11-14 1991-11-05 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives useful as adenosine receptor agonists
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US5036381A (en) 1990-06-15 1991-07-30 Motorola, Inc. Multiple electronic devices within a single carrier structure
GB2264948B (en) 1992-03-13 1996-10-16 Merck & Co Inc Human adenosine receptors
US5426101A (en) 1992-09-30 1995-06-20 Merrell Dow Pharmaceuticals Inc. 2-substituted adenosines with A-2 receptor affinity
WO1994023723A1 (en) 1993-04-15 1994-10-27 New York University Adenosine receptor agonists for the promotion of wound healing
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US5859019A (en) 1997-03-07 1999-01-12 Trustees Of The University Of Pennsylvania Methods for protecting against cardiac ischemia by administering adenosine A2a receptor antagonists
WO1998050047A1 (en) 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
WO1998052611A1 (en) * 1997-05-23 1998-11-26 Nippon Shinyaku Co., Ltd. Medicinal composition for prevention or treatment of hepatopathy
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6303619B1 (en) * 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response

Similar Documents

Publication Publication Date Title
CY2024006I2 (el) Διαμινοπυριμιδινες ως ρ2χ3 και ρ2χ2/3 ανταγωνιστες
WO2005027895A3 (en) Thyroid hormone analogs and methods of use in angiogenesis
WO2007075702A3 (en) Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
JP2004210767A5 (enExample)
JP2004515500A5 (enExample)
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
DK1414451T3 (da) Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
FR2798747B1 (fr) Composition de photoreserve contenant un generateur de photobase avec generateur de photo-acide
BR0311843A (pt) Métodos para prevenir, inibir, tratar ou reduzir esteatose hepática não- alcoólica em um animal e para prevenir o desenvolvimento e/ou a reversão do processo de nafld em um animal
JP2008532951A5 (enExample)
EP1621603A4 (en) DETERGENT COMPOSITION
JP2005516719A5 (enExample)
JP2002506648A5 (enExample)
DK1272897T3 (da) Adenosin-A2A-receptorantagonister til behandling og forebyggelse af leverfibrose, cirrose og fedtlever
EP1575571A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF A TUMOR
MXPA03009185A (es) Antagonistas de receptor a2a de adenosina combinados con compuestos de actividad neurotrofica en el tratamiento de la enfermedad de parkinson.
ATE285469T1 (de) Zusammensetzung zum reinigen von harten oberflächen
JP2007535560A5 (ja) Ａ１アデノシンレセプターアンタゴニストとしてのプリン誘導体
EP1470240A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES USING 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419 , 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2
EP3078386A3 (en) Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor
DE60326053D1 (de) Superfeine salmeterol zubereitung
EP1583966A4 (en) METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASES USING GENES 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33
JP2003526659A5 (enExample)
MXPA03003919A (es) Metodos y composiciones para estimular cd45 y de esta manera suprimir la activacion de microglia relacionada con enfermedad de alzheimer.
FR2886594B1 (fr) Volet d'arret sous siege